Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started
My Medicine

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Osteoporosis Health Center

Font Size

Evista Strengthens Bones, Safe on Uterus

Drug Reduces Osteoporosis Risk Without Raising Endometrial Cancer Risk

WebMD Health News

July 18, 2003 -- An osteoporosis drug that acts like estrogen in a woman's bones may be able to provide the bone-boosting effects of the hormone without the added risk of some types of cancer associated with estrogen.

New research shows that long-term use of the drug Evista can reduce a woman's risk of osteoporosis without increasing her risk of endometrial cancer.

Evista belongs to a class of drugs know as selective estrogen receptor modulators (SERMs) that have estrogen-like effects on bone tissue but may not act like the hormone estrogen in other parts of the body, such as the breast or uterus. But another SERM, tamoxifen, has been shown to increase the risk of endometrial cancer by stimulating the growth of endometrial tissue in the uterus.

In this report, published in the current issue of the journal Menopause, researchers combined data from two identical studies involving 328 women with an average age of 55 who were about five years past menopause. They were randomly assigned to take Evista or a placebo for 5 years.

Researchers found that women who took Evista were 87% less likely to develop spine osteoporosis, a condition of severe thinning of bone that increases the risk of fracture. They also found that women who had baseline osteopenia, a condition of thinned bone, were four times more likely to have normalized bone density at the spine and hip.

Women on Evista with normal bone densities at the start of the study were 77% less likely to develop thinning of the bone compared with women who took placebo.

No diagnoses of endometrial cancer were made in either treatment group.

Researcher Elaine E. Jolly, MD, of Ottawa General Hospital, and colleagues say this study provides the longest follow-up period to date on the osteoporosis drug's effects on the uterus and found no increased risk of endometrial cancer among women on Evista.

The study is funded by Eli Lilly and Co., the makers of Evista and a WebMD sponsor.

SOURCE: Menopause, July 2003. News release, Eli Lilly and Company.

Today on WebMD

Women working out and walking with weights
Reduce bone loss and build stronger muscles.
Chinese cabbage
Calcium-rich foods to add to your diet.
woman stretching
Get the facts on osteoporosis.
Porous bone
Causes, symptoms, risk factors, and treatment.
senior woman
Woman holding plate of brocolli
wrist xray
Superfood for Bones
mature woman
sunlight in hands
man and woman in front of xray
woman with dumbbells